Is KIDS or ENOV more profitable?

OrthoPediatrics has a net margin of -16.31% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat OrthoPediatrics' return on equity. Company Net Margins Return on Equity Return on Assets OrthoPediatrics -16.31% -7.01% -4.86% Enovis -49.92% 10.32% 4.57%

OrthoPediatrics (KIDS) Competitors

$19.95 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$19.92 -0.02 (-0.13%)

As of 07/2/2026 05:39 PM Eastern

Compare

KIDS vs. BFLY, PLSE, NVCR, EYE, and ENOV

Should you buy OrthoPediatrics stock or one of its competitors? MarketBeat compares OrthoPediatrics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OrthoPediatrics include Butterfly Network (BFLY), Pulse Biosciences (PLSE), NovoCure (NVCR), National Vision (EYE), and Enovis (ENOV). These companies are all part of the "medical equipment" industry.

How does OrthoPediatrics compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

OrthoPediatrics has higher revenue and earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	20.06	-$77.06M	-$0.30	N/A
OrthoPediatrics	$243.30M	2.11	-$39.65M	-$1.68	N/A

Butterfly Network has a beta of 2.05, indicating that its stock price is 105% more volatile than the broader market. Comparatively, OrthoPediatrics has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market.

Butterfly Network presently has a consensus target price of $5.56, suggesting a potential downside of 27.66%. OrthoPediatrics has a consensus target price of $24.44, suggesting a potential upside of 22.53%. Given OrthoPediatrics' stronger consensus rating and higher possible upside, analysts clearly believe OrthoPediatrics is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

37.9% of Butterfly Network shares are held by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are held by institutional investors. 22.0% of Butterfly Network shares are held by insiders. Comparatively, 32.7% of OrthoPediatrics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

OrthoPediatrics has a net margin of -16.31% compared to Butterfly Network's net margin of -73.63%. OrthoPediatrics' return on equity of -7.01% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-73.63%	-34.41%	-23.91%
OrthoPediatrics	-16.31%	-7.01%	-4.86%

In the previous week, Butterfly Network had 4 more articles in the media than OrthoPediatrics. MarketBeat recorded 4 mentions for Butterfly Network and 0 mentions for OrthoPediatrics. Butterfly Network's average media sentiment score of 0.33 beat OrthoPediatrics' score of 0.00 indicating that Butterfly Network is being referred to more favorably in the media.

Company	Overall Sentiment
Butterfly Network	Neutral
OrthoPediatrics	Neutral

Summary

OrthoPediatrics beats Butterfly Network on 11 of the 16 factors compared between the two stocks.

How does OrthoPediatrics compare to Pulse Biosciences?

OrthoPediatrics (NASDAQ:KIDS) and Pulse Biosciences (NASDAQ:PLSE) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

OrthoPediatrics has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market.

OrthoPediatrics has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OrthoPediatrics	$243.30M	2.11	-$39.65M	-$1.68	N/A
Pulse Biosciences	$751K	2,690.99	-$72.78M	-$1.10	N/A

In the previous week, Pulse Biosciences had 1 more articles in the media than OrthoPediatrics. MarketBeat recorded 1 mentions for Pulse Biosciences and 0 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.00 equaled Pulse Biosciences'average media sentiment score.

Company	Overall Sentiment
OrthoPediatrics	Neutral
Pulse Biosciences	Neutral

Pulse Biosciences has a net margin of 0.00% compared to OrthoPediatrics' net margin of -16.31%. OrthoPediatrics' return on equity of -7.01% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OrthoPediatrics	-16.31%	-7.01%	-4.86%
Pulse Biosciences	N/A	-86.67%	-73.61%

OrthoPediatrics currently has a consensus price target of $24.44, suggesting a potential upside of 22.53%. Pulse Biosciences has a consensus price target of $30.67, suggesting a potential upside of 5.02%. Given OrthoPediatrics' stronger consensus rating and higher possible upside, equities analysts plainly believe OrthoPediatrics is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

69.1% of OrthoPediatrics shares are owned by institutional investors. Comparatively, 76.9% of Pulse Biosciences shares are owned by institutional investors. 32.7% of OrthoPediatrics shares are owned by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

OrthoPediatrics beats Pulse Biosciences on 8 of the 15 factors compared between the two stocks.

How does OrthoPediatrics compare to NovoCure?

OrthoPediatrics (NASDAQ:KIDS) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

69.1% of OrthoPediatrics shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 32.7% of OrthoPediatrics shares are owned by company insiders. Comparatively, 5.5% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, NovoCure had 3 more articles in the media than OrthoPediatrics. MarketBeat recorded 3 mentions for NovoCure and 0 mentions for OrthoPediatrics. NovoCure's average media sentiment score of 0.38 beat OrthoPediatrics' score of 0.00 indicating that NovoCure is being referred to more favorably in the news media.

Company	Overall Sentiment
OrthoPediatrics	Neutral
NovoCure	Neutral

OrthoPediatrics has a net margin of -16.31% compared to NovoCure's net margin of -25.66%. OrthoPediatrics' return on equity of -7.01% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OrthoPediatrics	-16.31%	-7.01%	-4.86%
NovoCure	-25.66%	-50.82%	-16.48%

OrthoPediatrics currently has a consensus target price of $24.44, suggesting a potential upside of 22.53%. NovoCure has a consensus target price of $25.67, suggesting a potential upside of 49.22%. Given NovoCure's higher possible upside, analysts clearly believe NovoCure is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
NovoCure	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

OrthoPediatrics has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, NovoCure has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

OrthoPediatrics has higher earnings, but lower revenue than NovoCure. OrthoPediatrics is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OrthoPediatrics	$243.30M	2.11	-$39.65M	-$1.68	N/A
NovoCure	$674.41M	2.95	-$136.23M	-$1.53	N/A

Summary

OrthoPediatrics and NovoCure tied by winning 8 of the 16 factors compared between the two stocks.

How does OrthoPediatrics compare to National Vision?

OrthoPediatrics (NASDAQ:KIDS) and National Vision (NASDAQ:EYE) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

In the previous week, National Vision had 1 more articles in the media than OrthoPediatrics. MarketBeat recorded 1 mentions for National Vision and 0 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.00 equaled National Vision'saverage media sentiment score.

Company	Overall Sentiment
OrthoPediatrics	Neutral
National Vision	Neutral

National Vision has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OrthoPediatrics	$243.30M	2.11	-$39.65M	-$1.68	N/A
National Vision	$2.02B	0.78	$29.60M	$0.57	34.67

National Vision has a net margin of 2.31% compared to OrthoPediatrics' net margin of -16.31%. National Vision's return on equity of 6.41% beat OrthoPediatrics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OrthoPediatrics	-16.31%	-7.01%	-4.86%
National Vision	2.31%	6.41%	2.81%

OrthoPediatrics presently has a consensus price target of $24.44, indicating a potential upside of 22.53%. National Vision has a consensus price target of $30.08, indicating a potential upside of 52.24%. Given National Vision's higher probable upside, analysts plainly believe National Vision is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
National Vision	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

OrthoPediatrics has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, National Vision has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

69.1% of OrthoPediatrics shares are owned by institutional investors. 32.7% of OrthoPediatrics shares are owned by insiders. Comparatively, 2.4% of National Vision shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

National Vision beats OrthoPediatrics on 10 of the 15 factors compared between the two stocks.

How does OrthoPediatrics compare to Enovis?

OrthoPediatrics (NASDAQ:KIDS) and Enovis (NYSE:ENOV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Enovis had 4 more articles in the media than OrthoPediatrics. MarketBeat recorded 4 mentions for Enovis and 0 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.00 beat Enovis' score of -0.53 indicating that OrthoPediatrics is being referred to more favorably in the media.

Company	Overall Sentiment
OrthoPediatrics	Neutral
Enovis	Negative

OrthoPediatrics has a net margin of -16.31% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat OrthoPediatrics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OrthoPediatrics	-16.31%	-7.01%	-4.86%
Enovis	-49.92%	10.32%	4.57%

OrthoPediatrics has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Enovis has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

OrthoPediatrics has higher earnings, but lower revenue than Enovis. OrthoPediatrics is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OrthoPediatrics	$243.30M	2.11	-$39.65M	-$1.68	N/A
Enovis	$2.25B	0.58	-$1.18B	-$19.88	N/A

69.1% of OrthoPediatrics shares are owned by institutional investors. Comparatively, 98.5% of Enovis shares are owned by institutional investors. 32.7% of OrthoPediatrics shares are owned by company insiders. Comparatively, 2.9% of Enovis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

OrthoPediatrics currently has a consensus price target of $24.44, indicating a potential upside of 22.53%. Enovis has a consensus price target of $44.50, indicating a potential upside of 96.90%. Given Enovis' higher possible upside, analysts plainly believe Enovis is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Enovis	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

OrthoPediatrics and Enovis tied by winning 8 of the 16 factors compared between the two stocks.

Get OrthoPediatrics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KIDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KIDS vs. The Competition

Export

Metric	OrthoPediatrics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$512.42M	$7.57B	$7.16B	$12.48B
Dividend Yield	N/A	1.32%	2.66%	6.52%
P/E Ratio	-11.87	52.12	28.02	24.70
Price / Sales	2.11	49.46	540.37	99.49
Price / Cash	119.97	26.72	49.26	57.09
Price / Book	1.44	7.48	10.96	6.46
Net Income	-$39.65M	$159.19M	$3.57B	$337.01M
7 Day Performance	-1.72%	-0.39%	2.12%	1.69%
1 Month Performance	8.90%	-0.43%	5.25%	3.81%
1 Year Performance	-11.20%	3.14%	33.29%	23.90%

OrthoPediatrics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KIDS OrthoPediatrics	3.4438 of 5 stars	$19.95 flat	$24.44 +22.5%	-11.2%	$512.42M	$243.30M	N/A	200	Gap Down
BFLY Butterfly Network	1.3583 of 5 stars	$7.69 +5.8%	$5.56 -27.7%	+285.4%	$1.85B	$102.92M	N/A	460	News Coverage Gap Up
PLSE Pulse Biosciences	1.6838 of 5 stars	$25.95 +0.9%	$30.67 +18.2%	+97.4%	$1.78B	$350K	N/A	140
NVCR NovoCure	2.9595 of 5 stars	$14.13 +3.8%	$26.86 +90.1%	-2.9%	$1.58B	$655.35M	N/A	1,605	Gap Down
EYE National Vision	3.1336 of 5 stars	$16.78 -1.1%	$30.08 +79.3%	-17.3%	$1.36B	$1.99B	29.44	13,138	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KIDS) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OrthoPediatrics (KIDS) Competitors

KIDS vs. BFLY, PLSE, NVCR, EYE, and ENOV

How does OrthoPediatrics compare to Butterfly Network?

Summary

How does OrthoPediatrics compare to Pulse Biosciences?

Summary

How does OrthoPediatrics compare to NovoCure?

Summary

How does OrthoPediatrics compare to National Vision?

Summary

How does OrthoPediatrics compare to Enovis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KIDS vs. The Competition

OrthoPediatrics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OrthoPediatrics (KIDS) Competitors

KIDS vs. BFLY, PLSE, NVCR, EYE, and ENOV

How does OrthoPediatrics compare to Butterfly Network?

Which has stronger valuation and earnings, BFLY or KIDS?

Which has more risk and volatility, BFLY or KIDS?

Do analysts recommend BFLY or KIDS?

Do institutionals & insiders have more ownership in BFLY or KIDS?

Is BFLY or KIDS more profitable?

Does the media favor BFLY or KIDS?

Summary

How does OrthoPediatrics compare to Pulse Biosciences?

Which has more risk and volatility, KIDS or PLSE?

Which has preferable earnings and valuation, KIDS or PLSE?

Does the media refer more to KIDS or PLSE?

Is KIDS or PLSE more profitable?

Do analysts prefer KIDS or PLSE?

Do insiders & institutionals hold more shares of KIDS or PLSE?

Summary

How does OrthoPediatrics compare to NovoCure?

Do insiders and institutionals have more ownership in KIDS or NVCR?

Does the media favor KIDS or NVCR?

Is KIDS or NVCR more profitable?

Do analysts rate KIDS or NVCR?

Which has more risk & volatility, KIDS or NVCR?

Which has higher earnings and valuation, KIDS or NVCR?

Summary

How does OrthoPediatrics compare to National Vision?

Does the media refer more to KIDS or EYE?

Which has better valuation and earnings, KIDS or EYE?

Is KIDS or EYE more profitable?

Do analysts rate KIDS or EYE?

Which has more volatility and risk, KIDS or EYE?

Do insiders and institutionals hold more shares of KIDS or EYE?

Summary

How does OrthoPediatrics compare to Enovis?

Does the media refer more to KIDS or ENOV?

Is KIDS or ENOV more profitable?

Which has more risk and volatility, KIDS or ENOV?

Which has preferable earnings and valuation, KIDS or ENOV?

Do institutionals and insiders believe in KIDS or ENOV?

Do analysts rate KIDS or ENOV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KIDS vs. The Competition

OrthoPediatrics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools